Marinus Pharmaceuticals Inc Sample Contracts

Marinus Pharmaceuticals Inc – Ganaxolone for the Treatment of RSE September 26, 2019 Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstance (September 26th, 2019)
Marinus Pharmaceuticals Inc – AMENDED AND RESTATED EMPLOYMENT AGREEMENT (August 8th, 2019)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT dated as of August 6, 2019 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Scott Braunstein (the “Employee”).

Marinus Pharmaceuticals Inc – 2014 EQUITY INCENTIVE PLAN, AS AMENDED (August 8th, 2019)

The purpose of the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan is to provide (i) designated employees of Marinus Pharmaceuticals, Inc. (the “Company”) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the “Board”) with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock awards, stock units, stock appreciation rights and other equity-based awards. The Company believes that this Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefitting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders.

Marinus Pharmaceuticals Inc – Magnolia Part 2: (Top Line) Clinical Data Jess, change illustration Ganaxolone in PPD July 23, 2019 Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referenc (July 23rd, 2019)
Marinus Pharmaceuticals Inc – Re: Severance Agreement and General Release (March 20th, 2019)

We thank you for your service to Marinus Pharmaceuticals, Inc. (the “Company”). We are interested in resolving cooperatively your separation of employment with the Company, effective March 18, 2019 (the “Separation Date”), pursuant to Section 4(d) of your Amended and Restated Employment Agreement with the Company dated as of August 3, 2016 (the “Employment Agreement”). Toward this end, we propose the following Severance Agreement, which includes a General Release (the “Agreement”).

Marinus Pharmaceuticals Inc – EMPLOYMENT AGREEMENT (March 12th, 2019)

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of February 26, 2019 (the “Effective Date”), by and between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with offices at Three Radnor Corporate Center, 100 Matsonford Road, Suite 304, Radnor, PA 19087, and Scott Braunstein, an individual residing in Livingston, New Jersey (the “Executive”) (the Company and the Executive, together, the “Parties”).

Marinus Pharmaceuticals Inc – NEW YORK ATLANTA (December 14th, 2018)

We have acted as counsel to the Corporation in connection with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), of the Registration Statement and related prospectus supplement, relating to the proposed public offering by the Corporation (the “Offering”) of up to 13,800,000 shares (the “Shares”) of common stock, $.001 par value (“Common Stock”), of the Corporation.

Marinus Pharmaceuticals Inc – 12,000,000 Shares Marinus Pharmaceuticals, Inc. UNDERWRITING AGREEMENT (December 14th, 2018)

Introductory. Marinus Pharmaceuticals, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 12,000,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 12,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,800,000 Shares as provided in Section 2. The additional 1,800,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) and Leerink Partners LLC (“Leerink”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To

Marinus Pharmaceuticals Inc – Ganaxolone Data in PPD Studies December 10, 2018 Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are (December 10th, 2018)
Marinus Pharmaceuticals Inc – SECOND AMENDMENT TO LEASE (December 7th, 2018)

THIS SECOND AMENDMENT TO LEASE (“Amendment”) is made and entered into as of December 7, 2018, by and among RADNOR PROPERTIES-SDC, L.P., a Delaware limited partnership (“Current Landlord”), RADNOR CENTER ASSOCIATES, a Pennsylvania limited partnership (“New Landlord”), and MARINUS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. SENIOR DEBT SECURITIES (October 31st, 2017)

Indenture, dated as of [ • ], 20___, between Marinus Pharmaceuticals, inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. SUBORDINATED DEBT SECURITIES (October 31st, 2017)

Indenture, dated as of [ • ], 201___, between Marinus Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Marinus Pharmaceuticals Inc – NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO SHANGHAI TAIWAN BOSTON HOUSTON LOS ANGELES HANOI HO CHI MINH CITY FIRM and AFFILIATE OFFICES www.duanemorris.com ATLANTA BALTIMORE WILMINGTON MIAMI BOCA RATON PITTSBURGH NEWARK LAS VEGAS CHERRY HILL LAKE TAHOE MYANMAR OMAN A GCC REPRESENTATIVE OFFICE OF DUANE MORRIS ALLIANCES IN MEXICO AND SRI LANKA (September 15th, 2017)

We have acted as counsel to the Corporation in connection with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), of the Registration Statement and related prospectus supplement, relating to the proposed public offering by the Corporation (the “Offering”) of up to 10,733,334 shares (the “Shares”) of common stock, $.001 par value (“Common Stock”), of the Corporation.

Marinus Pharmaceuticals Inc – 9,333,334 Shares Marinus Pharmaceuticals, Inc. UNDERWRITING AGREEMENT (September 15th, 2017)
Marinus Pharmaceuticals Inc – Mindful Innovation Phase 2 Clinical Study Evaluating Ganaxolone in Children with CDKL5 Disorder September 11, 2017 Follow @MarinusPharma on Twitter! Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expression (September 11th, 2017)
Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN, AS AMENDED (August 1st, 2017)

The purpose of the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan is to provide (i) designated employees of Marinus Pharmaceuticals, Inc. (the “Company”) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the “Board”) with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock awards, stock units, stock appreciation rights and other equity-based awards. The Company believes that this Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefitting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders.

Marinus Pharmaceuticals Inc – EMPLOYMENT AGREEMENT (April 12th, 2017)

EMPLOYMENT AGREEMENT effective as of April 10, 2017, between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Lorianne Masuoka MD (the “Employee”).

Marinus Pharmaceuticals Inc – SUPPLY AGREEMENT (April 6th, 2017)

THIS SUPPLY AGREEMENT (this “Agreement”) is made this 31st day of March, 2017 (the “Effective Date”) between CyDex Pharmaceuticals, Inc., a Delaware corporation (“CyDex”), and Marinus Pharmaceuticals, Inc., a Delaware corporation (“Company”).

Marinus Pharmaceuticals Inc – LICENSE AGREEMENT (April 6th, 2017)

THIS LICENSE AGREEMENT (this “Agreement”) is made this 31st day of March, 2017 (the “Effective Date”) between CyDex Pharmaceuticals, Inc., a Delaware corporation (“CyDex”), and Marinus Pharmaceuticals, Inc., a Delaware corporation (“Company”). CyDex and Company are hereinafter individually referred to as a “Party” and collectively as the “Parties”.

Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. CHANGE IN CONTROL SEVERANCE PLAN (November 8th, 2016)

The Company has adopted this Marinus Pharmaceuticals, Inc. Change in Control Severance Plan for the benefit of certain employees of the Company, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intended to help retain qualified employees, maintain a stable work environment and provide economic security to eligible employees in the event of certain terminations of employment.

Marinus Pharmaceuticals Inc – EMPLOYMENT AGREEMENT (August 9th, 2016)

EMPLOYMENT AGREEMENT effective as of August 3, 2016 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Albena Patroneva (the “Employee”).

Marinus Pharmaceuticals Inc – Marinus Pharmaceuticals PROVIDES BUSINESS UPDATE AND REPORTS SECOND quarter 2016 FINANCIAL RESULTS (August 9th, 2016)

RADNOR, PA, August 9, 2016 (Globe Newswire) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2016.

Marinus Pharmaceuticals Inc – AMENDED AND RESTATED EMPLOYMENT AGREEMENT (August 9th, 2016)

EMPLOYMENT AGREEMENT effective as of August 3, 2016 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Edward F. Smith (the “Employee”).

Marinus Pharmaceuticals Inc – AMENDED AND RESTATED EMPLOYMENT AGREEMENT (August 9th, 2016)

EMPLOYMENT AGREEMENT effective as of August 3, 2016 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Christopher M. Cashman (the “Employee”).

Marinus Pharmaceuticals Inc – Mindful Innovation Exploratory Clinical Study Evaluating Ganaxolone for Behaviors in Children with Fragile X Syndrome June 28, 2016 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward (June 28th, 2016)
Marinus Pharmaceuticals Inc – FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (May 2nd, 2016)

This Fourth Amendment to Loan and Security Agreement (the “Amendment”), is entered into as of April 29, 2016, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and MARINUS PHARMACEUTICALS, INC. (“Borrower”).

Marinus Pharmaceuticals Inc – FIRST AMENDMENT TO LEASE (January 4th, 2016)

This First Amendment to Lease (“Amendment”) made and entered into this 28th day of December, 2015, by and between RADNOR PROPERTIES-SDC, L.P., a Delaware limited partnership, (“Landlord”) and Marinus Pharmaceuticals, Inc., a Delaware corporation (“Tenant”), and

Marinus Pharmaceuticals Inc – NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO SHANGHAI BOSTON HOUSTON LOS ANGELES HANOI HO CHI MINH CITY FIRM and AFFILIATE OFFICES www.duanemorris.com ATLANTA BALTIMORE WILMINGTON MIAMI BOCA RATON PITTSBURGH NEWARK LAS VEGAS CHERRY HILL LAKE TAHOE MYANMAR OMAN A GCC REPRESENTATIVE OFFICE OF DUANE MORRIS MEXICO CITY ALLIANCE WITH MIRANDA & ESTAVILLO SRI LANKA ALLIANCE WITH GOWERS INTERNATIONAL (November 6th, 2015)
Marinus Pharmaceuticals Inc – 5,000,000 Shares Marinus Pharmaceuticals, Inc. UNDERWRITING AGREEMENT (November 6th, 2015)
Marinus Pharmaceuticals Inc – THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (October 29th, 2015)

This Third Amendment to Loan and Security Agreement (the “Amendment”), is entered into as of October 29, 2015, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and MARINUS PHARMACEUTICALS, INC. (“Borrower”).

Marinus Pharmaceuticals Inc – Marinus Pharmaceuticals PROVIDES business UPDATE and reports third quarter 2015 financial results (October 29th, 2015)

RADNOR, PA, October 29, 2015 (Globe Newswire) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2015.

Marinus Pharmaceuticals Inc – SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (October 29th, 2015)

This Second Amendment to Loan and Security Agreement (the “Amendment”), is entered into as of February 2, 2015, by and between SQUARE 1 BANK (“Bank”) and MARINUS PHARMACEUTICALS, INC. (“Borrower”).

Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. SENIOR DEBT SECURITIES (August 13th, 2015)

Indenture, dated as of [ • ], 201___, between Marinus Pharmaceuticals, inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Marinus Pharmaceuticals Inc – MARINUS PHARMACEUTICALS, INC. SUBORDINATED DEBT SECURITIES (August 13th, 2015)

Indenture, dated as of [ • ], 201___, between Marinus Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Marinus Pharmaceuticals Inc – Marinus Pharmaceuticals PROVIDES BUSINESS UPDATE AND REPORTS SECOND quarter 2015 FINANCIAL RESULTS (August 4th, 2015)

RADNOR, PA, August 4, 2015 (Globe Newswire) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2015.